- Home
- DQ vs ADPT Comparison
DQ vs ADPT Comparison
Compare DQ & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DQ
- ADPT
- Stock Information
- Founded
- DQ 2006
- ADPT 2009
- Country
- DQ China
- ADPT United States
- Employees
- DQ N/A
- ADPT N/A
- Industry
- DQ Semiconductors
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DQ Technology
- ADPT Health Care
- Exchange
- DQ Nasdaq
- ADPT Nasdaq
- Market Cap
- DQ 1.7B
- ADPT 1.8B
- IPO Year
- DQ 2010
- ADPT 2019
- Fundamental
- Price
- DQ $25.78
- ADPT $13.67
- Analyst Decision
- DQ Buy
- ADPT Strong Buy
- Analyst Count
- DQ 4
- ADPT 8
- Target Price
- DQ $30.84
- ADPT $12.38
- AVG Volume (30 Days)
- DQ 1.4M
- ADPT 1.7M
- Earning Date
- DQ 10-29-2025
- ADPT 11-06-2025
- Dividend Yield
- DQ N/A
- ADPT N/A
- EPS Growth
- DQ N/A
- ADPT N/A
- EPS
- DQ N/A
- ADPT N/A
- Revenue
- DQ $592,959,000.00
- ADPT $205,216,000.00
- Revenue This Year
- DQ N/A
- ADPT $32.76
- Revenue Next Year
- DQ $69.31
- ADPT $15.81
- P/E Ratio
- DQ N/A
- ADPT N/A
- Revenue Growth
- DQ N/A
- ADPT 21.60
- 52 Week Low
- DQ $12.41
- ADPT $3.98
- 52 Week High
- DQ $30.85
- ADPT $13.68
- Technical
- Relative Strength Index (RSI)
- DQ 53.37
- ADPT 60.88
- Support Level
- DQ $25.61
- ADPT $12.59
- Resistance Level
- DQ $27.94
- ADPT $13.68
- Average True Range (ATR)
- DQ 1.59
- ADPT 0.66
- MACD
- DQ -0.17
- ADPT -0.01
- Stochastic Oscillator
- DQ 36.18
- ADPT 94.66
About DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).